Humacyte gets Nasdaq notice after shares trade below $1 bid-price minimumPUBT·2 days ago, 04:01 PMHUMA-2.71%
BTIG Research Reaffirms Buy Rating for Humacyte (NASDAQ:HUMA)Market Beat·Jul 28 at 12:18 PMHUMA-2.71%
Supply Chain Shifts and Consumer Crosscurrents: A Look at 10 US-Listed Equities Navigating Macro HeadwindsGlobal Report·Jul 22 at 04:18 AMPGY+9.24%NB-1.05%
Humacyte names nephrologists Kossmann, Roy-Chaudhury as dialysis access advisorsPUBT·Jul 14 at 07:07 AMHUMA-2.71%
The Heterogeneity of Value Chains: From Synthetic Biology to Cloud AggregatorsGlobal Report·Jul 14 at 06:47 AMDDOG-0.22%TWST+0.24%
The Market’s Misfit Toys: Who’s Actually Executing and Who’s Fast Asleep?Global Report·Jul 9 at 09:02 PMFRST+0.75%KRKR+4.73%
From Candy to Graphite: The Surreal Pivots of 2026's Small-Cap MarketGlobal Report·Jul 9 at 05:02 AMABAT+2.45%AEVA+6.56%
The Physical Constraints of Aggregation: 10 Case Studies from the Market's Long TailGlobal Report·Jul 8 at 10:32 PMINV-2.72%USEA-2.59%
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga_article·Jul 1 at 04:05 PMCMMB+1.31%CRIS+1.21%
Pre-market hot trades in US stocks: Humacyte up 7.25% pre-market; Lam Research up 3.62% pre-marketPrice Alert·Jun 29 at 05:37 AMHUMA-2.71%LRCX-1.58%
